top of page
  • Recruiting
    • Jun 11, 2021

NCT04754945: Phase 1: Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis

NCT04754945: Phase 1: Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis


isatuximab

NCT04754945: Phase 1: Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis


This phase I trial studies the side effects of isatuximab and to see how well it works in treating patients with high risk immunoglobulin light chain amyloidosis (AL amyloidosis). Isatuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.


Sponsor

Emory University


Collaborators

Sanofi

National Cancer Institute (NCI)


Information provided by (Responsible Party)

Craig Hofmeister, Emory University

 

ClinicalTrials.gov Identifier: NCT04754945